Provided by Tiger Fintech (Singapore) Pte. Ltd.

Olema Pharmaceuticals, Inc.

4.60
-0.0700-1.50%
Post-market: 4.50-0.1000-2.17%19:44 EDT
Volume:468.47K
Turnover:2.17M
Market Cap:314.33M
PE:-2.09
High:4.80
Open:4.70
Low:4.51
Close:4.67
Loading ...
May 09, 2023

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Apr 10, 2023

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Mar 29, 2023

Proposed Sale Of Securities

144 - Report of proposed sale of securities
Mar 22, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Mar 10, 2023

Major Issues Report

8-K - Current report
Mar 09, 2023

Major Issues Report

8-K - Current report
Mar 09, 2023

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 09, 2023

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Feb 14, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 10, 2023

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 09, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 06, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Dec 16, 2022

Major Issues Report

8-K - Current report
Nov 14, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Nov 08, 2022

Major Issues Report

8-K - Current report
Nov 08, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 09, 2022

Major Issues Report

8-K - Current report
Aug 09, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Jun 23, 2022

Major Issues Report

8-K - Current report